Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Alaunos Therapeutics
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05292859CT.gov Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | — | Completed | — | — | — |
NCT05194735CT.gov Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoantigen Specific Tcr-T Cell Drug Product (this asset) | Alaunos Therapeutics | P1/2 | CCC · 48 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Canfosfamide | Telik | P3 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Nogitecan | GlaxoSmithKline | P3 | B |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Neoantigen Specific Tcr-T Cell Drug Product
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adenosquamous Lung Carcinoma | — | P1/2 | CCC · 48 |
| Lung Adenocarcinoma | — | P1/2 | CCC · 48 |
| Squamous Cell Lung Carcinoma | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Neoantigen Specific Tcr-T Cell Drug Product in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/neoantigen-specific-tcr-t-cell-drug-product-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →